Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517619 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
A Phase 3 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
NCT02517619 is a Phase 3 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 251 participants.
The verdict
NCT02517619, a Phase 3 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Interventions
- DRUG Dexamethasone Phosphate Ophthalmic Solution
- DRUG Prednisolone Acetate Ophthalmic (1%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2016-01-16 |
| Est. Completion | 2018-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02517619
The ClinicalTrials.gov registry entry for NCT02517619 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyegate Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Phosphate Ophthalmic Solution is the first listed.
NCT02517619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02517619 about?
NCT02517619 is a clinical study titled "Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis". The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior seg...
What is the current status of trial NCT02517619?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2016-01-16. Estimated completion is 2018-05-29.
What interventions are being tested in trial NCT02517619?
The interventions under investigation include: Dexamethasone Phosphate Ophthalmic Solution (DRUG), Prednisolone Acetate Ophthalmic (1%) (DRUG).
Who is sponsoring clinical trial NCT02517619?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.